Interferon-naive patients with chronic HCV infection ( n = 187 ) were randomly chosen to receive 15 microg CIFN or 9 microg or 3 MU IFN-alpha-2a subcutaneously , three times a week for 24 weeks , followed by a 24 week observation period .
